4.7 Article

SARS-CoV-2 prolonged infection during advanced HIV disease evolves extensive immune escape

Journal

CELL HOST & MICROBE
Volume 30, Issue 2, Pages 154-+

Publisher

CELL PRESS
DOI: 10.1016/j.chom.2022.01.005

Keywords

-

Funding

  1. Bill and Melinda Gates Foundation [INV-018944]
  2. National Institutes of Health [R01 AI138546, U01 AI151698]
  3. South African Medical Research Council
  4. South African Research Chairs Initiative of the Department of Science and Innovation
  5. NRF [9834]
  6. Bill and Melinda Gates Foundation [INV-018944] Funding Source: Bill and Melinda Gates Foundation

Ask authors/readers for more resources

Characterizing the evolution of SARS-CoV-2 in an individual with advanced HIV disease in South Africa, this study found that the evolved virus showed immune escape of vaccines and enhanced escape of Delta immunity. This suggests that immune-compromised hosts may play a significant role in the evolution of the virus.
Characterizing SARS-CoV-2 evolution in specific geographies may help predict properties of the variants that come from these regions. We mapped neutralization of a SARS-CoV-2 strain that evolved over 6 months from ancestral virus in a person with advanced HIV disease in South Africa; this person was infected prior to emergence of the Beta and Delta variants. We longitudinally tracked the evolved virus and tested it against self plasma and convalescent plasma from ancestral, Beta, and Delta infections. Early virus was similar to ancestral, but it evolved a multitude of mutations found in Omicron and other variants. It showed substantial but incomplete Pfizer BNT162b2 escape, weak neutralization by self-plasma, and despite pre-dating Delta, it also showed extensive escape of Delta infection-elicited neutralization. This example is consistent with the notion that SARS-CoV-2 evolving in individual immune-compromised hosts, including those with advanced HIV disease, may gain immune escape of vaccines and enhanced escape of Delta immunity, and this has implications for vaccine breakthrough and reinfections.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available